SAN DIEGO, June 1, 2017 /PRNewswire/ -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced that it will present results from two studies featuring the company's Decipher Genomics Resource Information Database (Decipher GRID®) and Decipher® Prostate Cancer Classifier tests at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 2nd to 6th in Chicago, IL.
Oral Abstract Session:
Title: Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk
Abstract No: 5000
Date: Saturday, June 3, 2017
Location: Hall B1 (1:15 p.m. to 1:27 p.m. CDT)
Presenter: Daniel Spratt, M.D., University of Michigan
Title: Association of loss of tumor suppressor ZFP36 with lethal prostate cancer
Abstract No: 5062
Date: Monday, June 5, 2017
Poster Session: Hall A (1:15 p.m. to 4:45 p.m. CDT)
Presenter: Christopher Sweeney, MBBS, Dana-Farber Cancer Institute
About Decipher GRID® and Cancer Classifier Tests
GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.
About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedxs-decipher-to-be-featured-in-multiple-presentations-at-asco-2017-300466852.html
SOURCE GenomeDx Biosciences